MariMed Inc (MRMD)
OTHER OTC:MRMD
MRMD Stock Chart & Stats
$0.08
<$0.01(0.85%)
At close: 4:00 PM EST
$0.08
<$0.01(0.85%)
Day’s Range― - ―
52-Week Range$0.06 - $0.23
Previous CloseN/A
Volume101.75K
Average Volume (3M)1.40M
Market Cap
$26.46M
Enterprise Value$117.86M
Total Cash (Recent Filing)$8.88M
Total Debt (Recent Filing)$100.09M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 13, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding397,882,750
10 Day Avg. Volume1,629,378
30 Day Avg. Volume1,398,937
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.66
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market Cap4.45
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit2.03
Enterprise Value/Ebitda12.48
Forecast
1Y Price Target
$0.25Price Target Upside212.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$164.30M
Bulls Say, Bears Say
Bulls Say
Revenue Scale & GrowthMariMed has built meaningful scale with roughly $160M in FY2025 revenue after multi‑year expansion. Durable scale across cultivation, manufacturing and retail supports bargaining power with retailers, fixed‑cost absorption, and the ability to invest in product and distribution for sustained growth.
Wholesale & Distribution ReachA growing wholesale channel that now comprises ~44% of revenue and expanded penetration into new markets creates a durable revenue base less tied to retail foot traffic. Broad dispensary penetration supports national brand placement, scale benefits in production, and diversified demand across jurisdictions.
Cash Generation & EBITDA TractionConsistent adjusted EBITDA and 2025 positive free cash flow indicate improving cash conversion and operational resilience. Persistent positive cash generation provides runway to fund selective investments, support working capital in volatile markets, and reduces reliance on dilutive equity over the medium term.
Bears Say
Strained Capital StructureSharp rise in debt relative to a diminished equity base materially weakens financial flexibility. High leverage amplifies downside in revenue shocks, increases fixed interest burden, and constrains ability to invest or pursue M&A without further refinancing or dilutive capital, a lasting structural constraint.
Margin Compression & Persistent LossesSustained margin erosion reduces internal cash generation and limits reinvestment capacity. Ongoing pricing pressure in mature markets suggests structural competitiveness issues; without durable margin recovery, profitability and return metrics may remain weak despite revenue scale.
Restructuring Raises Dilution And Senior ClaimsThe preferred‑stock restructuring removed near‑term cash strain but establishes senior claims and conversion options that can dilute common holders and prioritize creditor claims. This tradeoff improves near‑term liquidity but structurally elevates future dilution risk and increases effective cost of capital.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was $0.06 and its highest was $0.23 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is $26.46M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is May 13, 2026 which is in 38 days.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on Mar 11, 2026. The company reported $0.006 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.016.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Undervalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 397,882,750 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of $0.006 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MariMed Inc
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
MRMD Company Deck
MRMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic tone: MariMed reported continued brand and wholesale momentum (category leadership, expanded penetration, wholesale growth, Delaware AU traction), maintained positive adjusted EBITDA streak, and executed balance sheet actions to improve flexibility. However, the company is facing notable margin and retail headwinds in mature markets (notably Illinois and Massachusetts), experienced declines in EBITDA and operating income YoY, and has limited near‑term cash reserves. Management emphasized disciplined cost control, asset‑light licensing expansion, and selective M&A, while acknowledging timing risk for new market contributions.View all MRMD earnings summariesMRMD Stock 12 Month Forecast
Average Price Target
$0.25
▲(212.50% Upside)
Technical Analysis
Ownership Overview
10.70% Insiders
0.26% Other Institutional Investors
89.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---